This is a retrospective analysis of 10 mg metoclopramide, 25 mg diphenhydramine, and 4 mg dexamethasone given intravenous piggyback every 6 hours for nausea or vomiting. Outcome measures were rapidity of symptom relief based on the self-report of the patient and nursing documentation of relief from symptoms of nausea or vomiting. Seven hundred and ninety seven patients were admitted to the inpatient hospice unit during a 2-year period. Sixty-three patients developed nausea or vomiting requiring the cocktail. Fifty-seven patients (90%) had objective response as reflected in nursing notes. Symptom relief was usually noted within 2 days with improvement in oral intake and enjoyment in activities, such as parties and family interactions. Partial relief was noted in patients with gastrointestinal malignancies and peritoneal carcinomatosis even with the addition of other antiemetics to the cocktail.
Reuben DB, Mor V.Nausea and vomiting in terminal cancer patients. Arch Intern Med. 1986;146:2021-2023.
2.
Baines M.Nausea and vomiting in the patient with advanced cancer. J Pain Symptom Manage. 1988;3:81-85.
3.
Bruera E.Update on adjuvant drugs in patients with cancer. In: Bond MR, Charlton JE , Woolf CJ, eds. Proceedings World Congress on Pain . New York, NY: Elsevier Science Publications BV;1991;459-465.
4.
Curtis EB, Krech R., Walsh TDCommon symptoms in patients with advanced cancer. J Palliative Care. 1991; 7:25-29.
5.
Bruera E., Seifert L., Watanabe S., et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996;11:147-153.
6.
Pereira J., Bruera E.Chronic nausea. In: Bruera E, Higginson I, eds. Cachexia-Anorexia in Cancer Patients. Oxford, England: Oxford University Press, 1996;2:23-37.
7.
Nelson KA, Walsh DT, Sheehan FG, O'Donovan PB, Falk GWAssessment of upper gastrointestinal motility in the cancer associated dyspepsia syndrome. J Palliat Care. 1993;9:27-31.
8.
Perkel MS, Moore CHT, Davidson EDMetoclopramide therapy in patients with Delayed gastric emptying: a randomized, double blind study. Dig Dis Sci. 1979;24: 662-666.
9.
Snape WJ, Battle WM, Scwartz SS, Braunstein SN, Goldstein HA, Avali A.Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med. 1982; 96:444-446.
10.
McCallum RW , Ricci DA, Rakatansky H., et al. A multicenter placebo controlled clinical trial of oral metoclopramide in diabetic gastroparesis . Diabetes Care. 1983;6:463-467.
11.
Loo FD, Palmer DW, Soergel KH, Kalbfleisch JH, Wood CMGastric emptying in patients with diabetes mellitus. Gastroenterology . 1984;86:485-494.
12.
Shade RR, Dugas MC, Lhotsky DM, Gavaler JS, AanThiel DHEffect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10-15.
13.
Dundee JW, Clarke RSJ.The premedicant and antiemetic action of metoclopramide. Postgrad Med J. 1973; 49(suppl 4):34-38.
14.
Assaf RAE , Clarke RSJ , Dundee JW, Samuel IOStudies of drugs given before anesthesia XXIV: metoclopramide and morphine and pethidine. Br J Anaesth . 1974;46: 514-519.
15.
Gay L., Carliner P.The prevention and treatment of motion sickness. Bull Johns Hopkins Hosp. 1949;49:470-479.
16.
Kleinerman K.Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. Ann Pharmacother. 1993;27:566-568.
17.
Gonzales-Rosales F., Walsh D.Intractable nausea and vomiting due to gastrointestinal mucosal metastasis relieved by tetra-hydrocannabinol (Dronabinol). J Pain Symptom Manage. 1997 ;14:311-314.
Milner WD, Sanger GHInhibition of cisplatin-induced vomiting by selective 5-hydroxy tryptamine M-receptor antagonism. Br J Pharmacol. 1986 ;88:497-499.
20.
Fozard JRBasic mechanism of antimigraine drugs. In: Critchley M, Friedman AP, Goroni AS, Sicuter F , eds. Advances in Neurology. Headache: Physiopathological and Clinical Concepts. New York, NY: Raven Press;1982:295-307.
21.
Fozard JR, Atm Mabarok Ali.Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmac. 1978;49:109-112.
22.
Ripamonti C. , Rodriguez C.Gastrointestinal motility disorders in patients with advanced cancer. In: Russell KP, Eduardo B, eds. Topics in Palliative Care. New York, NY: Oxford University Press;1997:61-93.
23.
Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RCMetoclopramide: an updated review of its pharmacologic properties and clinical use. Drugs. 1983;25:451-494.
24.
Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med. 1981; 16:905-909.
25.
Schwartz J-C., Agid Y., Bouthenet M-L., et al. Neuro-chemical investigations into the human area postrema. In: Davis CJ, Lake-Bakaar GV, Graham-Smith DG, eds. Nausea and Vomiting: Mechanisms and Treatment. Berlin, Germany: Springer-Verlag; 1986:10-17.
26.
Bruera E., MacEachern T., Spachynski K., et al. Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 1997;74:3204-3211.
27.
Rubin A., Winston J.The role of the vestibular apparatus in the production of nausea and vomiting following the administration of morphine to man. J Clin Invest . 1958;29:1261.
28.
Borrison HL , Wang SCPhysiology and pharmacology of vomiting. Pharmacol Rev. 1953;5:193-230.
29.
Allan SG, Cornbleet MA, Warrington PS, Golland IM, Leonard RCF, Smyth JNDecadron and high dose metoclopramide: efficacy in controlling cisplatin induced nausea nad vomiting. BMJ. 1984;289:878-879.
30.
Grunberg SM , Akerly WL, Krailo MD, Johnson KB, Baker CR, Cariffe PAComparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatin-induced emesis. Cancer Invest. 1986;4:379-385.
31.
Roila F., Tonato M., Cognetti F., et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone . J Clin Oncol. 1991; 9:675-678.
32.
Smyth JF, Coleman RE, Nicolson M., et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondasetron? BMJ. 1991;303:1423-1426.
33.
Breura E., Moyano JR, Sala R., et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage. 2004;28:381-388.
34.
Bruera E., Brenneis C., Michaud M., Partington J., Paterson AH, MacDonald RNContinuous subcutaneous (SC) infusion of metoclopramide (MCP) using a plastic disposable infusor for the treatment of chemotherapy-induced emesis . J Pain Symptom Manage. 1988;3:105-109.
35.
Bruera E., Brenneis C., MacDonald RN, Michaud M.Continuous sc infusion of metoclopramide for treatment of narcotic bowel syndrome . Cancer Treat Rep. 1987;71: 1121-1122.
36.
Hardy J., Daly S., McQuade B., et al. A double-blind, randomized, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o with placebo and metoclopramide 10mg t.d.s p.o in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10:231-236.
37.
Oettle H., Riess H.Treatment of chemotherapy-induced nausea and vomiting. J Cancer Res Clin Oncol. 2001; 127:340-345.
38.
Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3:1379-1384.
39.
Morrow GR, Hckok JT, Rosenthal SNProgress in reducing nausea and emesis. Comparisons of Ondansetron, granisetron, and tropisetron. Cancer. 1995 ;76:343-357.
40.
Ned Tijdschr Geneeskd.New developments in the treatment of nausea and vomiting caused by chemotherapy . 2003;147:690
41.
Silvey L., Carpenter J., Wheeler R., Lee J., Conolley C.A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol. 1988; 6:1397-1400.
42.
Bruera E., Roca E., Cedaro L., Chacon R., Estevez R.Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 1983;67:381-383.
43.
Manara L., Bianchetti A.The central and peripheral influence of opioids on gastrointestinal propulsion . Ann Rev Pharmacol Toxicol. 1985 ;25:249-273.
44.
Robostelli DCC , Pellegrini A., Piazzi M.Effect of methylprednisolone sodium succinate on quality of life in pre-terminal cancer patients: a placebo controlled multi-center study. Eur J Cancer. 1989;25:1817-1821.
45.
Watanabe S. , Bruera E.Corticosteroids in adjuvant analgesics . J pain Symptom Manage. 1994;9:442-445.
46.
Loprinzi C.Management of cancer anorexia/cachexia. Support Care Cancer. 1995;3:120-122.
